PRESS RELEASE 18 June 2025

ReciBioPharm celebrates strong first half of 2025 with momentum for the future

- *First half of 2025 positions Recipharm's advanced biologics business for further success in the remainder of the year*
- *xRNA breakthrough: RNA production cut from 25 to 5 days*
- *Strategic growth with key partners and expanded portfolio.*

ReciBioPharm, Recipharm's Advanced Biologics segment, a leading global ATMP contract development and manufacturing organisation, is marking a highly successful first half of 2025, highlighted by strategic partnerships, technological progress and expanded service offerings.

Earlier this year, ReciBioPharm announced it had received a grant from the Gates Foundation to accelerate development of its xRNA platform. The initiative is designed to support the deployment of a scalable, continuous manufacturing process for xRNA vaccines and therapeutics, with the goal of improving access in low- and middle-income countries (LMICs).

ReciBioPharm also made significant strides in the development of its xRNA continuous manufacturing platform, already delivering a major leap in productivity by reducing RNA production timelines from 25 days to just 5 at the process development scale, demonstrating its potential to scale up and deliver rapid, cost-effective solutions for global health challenges.

ReciBioPharm recently announced it has extended its collaboration with the University of Oxford, to support the clinical development of two blood-stage malaria vaccine candidates. ReciBioPharm is leading the GMP manufacturing of drug substance, drug product and large-scale fill and finish operations for both R78C and RH5.1, as they advance into Phase 1/2 clinical trials. This builds on a partnership that began in 2016 and has already delivered five candidates. ReciBioPharm aims to streamline the pathway from laboratory discovery to clinical application, accelerating the translation of these vaccine candidates into potential global health interventions.

Further reinforcing its capabilities, ReciBioPharm expanded its portfolio through a licensing agreement with NewBiologix for its Xcell-Eng-HEK293 cell line, a cGMP-ready, high-yield solution specifically optimised for recombinant adeno-associated virus (rAAV) production. Integrated into Recipharm's AAV manufacturing platform, this cell line consistently delivers vector genome titres exceeding 2×10^{15} vg/L, even with complex (~5 kb) gene constructs, and achieves over 95 % full capsids in the final product. Validated across more than ten rAAV serotypes, the technology supports scalable production from research-use-only through to GMP manufacturing, streamlining development timelines for cell and gene therapies.

With these developments, ReciBioPharm is on track for a record year, reflecting growing demand and confidence in its end-to-end service model.

"We are entering the second half of 2025 well positioned for success," said Vikas Gupta, President, ReciBioPharm. "Every milestone this year is a testament to the passion and purpose of our global team, and to our unwavering focus on making advanced biologics more accessible and impactful than ever before."

In addition to its progress across RNA, AAV, and analytical services, ReciBioPharm offers an integrated suite of capabilities spanning a broad range of advanced modalities. These include viral vectors, plasmid, nucleic acid, RNA-based therapeutics, cell therapies and microbiome. With deep expertise across development, scale-up, and GMP manufacturing, the segment supports clients from early-stage innovation through to late-phase and commercial production. Its global network of specialised facilities enables flexible, end-to-end solutions tailored to the unique demands of advanced therapy programmes.

For more information

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Biologics division works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm, please visit www.recipharm.com and www.recibiopharm.com

Media contact:

Guenaelle Holloway, Head of communications
Guenaelle.Holloway@recipharm.com
+44 7730 303 708